Rocket Lab Corp is engaged in space, building rockets, and spacecraft... Show more
Rocket Lab USA is a vertically integrated aerospace company providing launch services, satellite manufacturing, spacecraft components, and space systems to commercial, government, and defense customers. The company's Electron rocket is the world's most frequently launched orbital small rocket, while its HASTE vehicle serves hypersonic test launch missions for the U.S. Department of Defense. Rocket Lab is also developing Neutron, a medium-lift reusable rocket designed to compete with SpaceX's Falcon 9 in the constellation deployment and national security markets. With a record backlog of $2.2 billion as of Q1 2026 and more than 70 contracted missions, Rocket Lab is the second-most-used launch provider in the United States behind SpaceX. The company is headquartered in Long Beach, California, and trades on the Nasdaq under the ticker RKLB.
RKLB shares closed at $63.91 on July 24, 2026, marking a decline of approximately 25% from the June 24 close of $85.41. The stock briefly rallied above $100 in the days immediately following the Iridium acquisition announcement on June 29 before heavy selling pressure took hold. Over the last quarter, the stock has been exceptionally volatile: shares traded near $80 in late April before skyrocketing to an all-time high of $150.23 on May 27 amid the SpaceX IPO-fueled space sector rally. Since that peak, RKLB has shed roughly 57% of its value, erasing all of its year-to-date gains and then some. The quarterly decline from approximately $79.68 on April 24 to $63.91 on July 24 represents a drop of roughly 20%, though the path between those two points included one of the most dramatic boom-and-bust cycles in the stock's history.
The dominant catalyst over the past 30 days was Rocket Lab's June 29 announcement of an $8 billion cash-and-stock acquisition of Iridium Communications (IRDM), the satellite communications operator with 66 low-Earth-orbit satellites and 2.5 million subscribers. While the deal's strategic logic — adding recurring communications revenue and making Rocket Lab a direct competitor to SpaceX's Starlink — initially sent shares surging over 20%, sentiment quickly soured as investors digested the $3.6 billion in bridge financing from Deutsche Bank and Wells Fargo, the significant share dilution required, and the integration complexity of absorbing a company with $871.7 million in annual revenue. A previously disclosed $1 billion at-the-market equity offering program, revealed in a June 22 SEC filing, compounded dilution fears.
Insider selling added further pressure. CEO Peter Beck sold approximately 3.28 million shares at an average price of $87.43 between late June and July 8 under a pre-announced trading plan, generating roughly $286 million. Though the sale was disclosed in March, the timing coincided with the stock's post-acquisition weakness. On July 15, Piper Sandler initiated coverage with a Neutral rating and an $83 price target, with analyst Alexander Potter flagging that RKLB still trades at a premium valuation relative to peers even after the sell-off — shares dropped more than 11% in that session alone. The broader space sector also continued to deteriorate, with the Procure Space ETF (UFO) falling 37% from its 2026 high and SpaceX (SPCX) sliding from $225 to $110, reflecting a broad rotation out of space names.
The last quarter tells a story of two extremes. In early May, Rocket Lab reported Q1 2026 results that surpassed all guidance metrics: record revenue of $200.35 million (up 63.5% year-over-year), record gross margins of 38.2%, and a backlog reaching $2.2 billion. Management guided for Q2 revenue of $225 million to $240 million, well above consensus. The SpaceX IPO in late May ignited a sector-wide rally that propelled RKLB to $150.23 on May 27. However, that enthusiasm proved fleeting. Once the IPO rotation trade exhausted itself, valuations across the entire space complex came under scrutiny. Rocket Lab, trading at roughly 66 times trailing sales while still unprofitable with a net loss of $198 million in fiscal 2025, became a prime target for profit-taking. The Iridium deal, while strategically ambitious, introduced fresh uncertainty — investors are now pricing in execution risk, dilution, and the challenge of integrating a mature communications business into a company still investing heavily in Neutron development.
For traders looking to navigate volatile stocks like Rocket Lab with discipline and data-driven precision, Tickeron's Trending AI Robots page offers a curated view into the platform's most relevant AI-powered trading strategies. Tickeron hosts hundreds of AI trading bots that actively trade thousands of tickers across a wide range of strategies, timeframes, and performance profiles. Rather than surfacing every bot, the Trending AI Robots section highlights only those demonstrating standout performance and relevance in current market conditions. Each bot employs distinct technical, fundamental, or pattern-recognition methodologies, giving traders the flexibility to align automated strategies with their own risk tolerance and investment objectives. Exploring this section can help investors identify tools that complement their approach to rapidly moving stocks.
The most immediate catalyst for RKLB is the Q2 2026 earnings report expected on August 6. Investors will scrutinize whether revenue landed within management's guidance range of $225 million to $240 million, any updates to the Neutron debut timeline — widely regarded as the single most important variable for the long-term investment thesis — and commentary on the Iridium acquisition's closing timeline and integration planning. Backlog growth, which stood at $2.2 billion last quarter, will be another critical metric. Beyond earnings, regulatory and shareholder approval progress on the Iridium deal, the pace of additional at-the-market equity issuances, and any further insider selling disclosures will influence near-term sentiment. Macroeconomic factors, including interest rate movements and risk appetite for unprofitable growth stocks, also remain relevant. While consensus analyst ratings remain predominantly bullish with an average price target near $110, the disconnect between strong operational execution and deteriorating share prices underscores the importance of watching both fundamentals and sentiment signals closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RKLB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 29 cases where RKLB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator entered the oversold zone -- be on the watch for RKLB's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for RKLB just turned positive on July 06, 2026. Looking at past instances where RKLB's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RKLB advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RKLB as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
RKLB moved below its 50-day moving average on June 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RKLB crossed bearishly below the 50-day moving average on June 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RKLB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for RKLB entered a downward trend on July 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RKLB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.637) is normal, around the industry mean (9.810). P/E Ratio (0.000) is within average values for comparable stocks, (119.202). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.074). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (52.356) is also within normal values, averaging (34.934).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry AerospaceDefense